Home・Elenco Azioni・AtriCure Inc

AtriCure Inc

Aperta

SettoreSettore sanitario

39.02 1.51

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

38.35

Massimo

39.19

Metriche Chiave
By Trading Economics
Entrata	8.8M 9M
Vendite	12M 154M
P/E Media del settore	177.952 64.641
EPS	0.18
Margine di Profitto	5.83
Dipendenti	1,350
EBITDA	-3.8M 3.2M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+22.13% upside

Dividendi
By Acuity
Utili prossimi	28 ott 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	132M 1.9B
Apertura precedente	37.51
Chiusura precedente	39.02

Notizie sul Sentiment di mercato

By Acuity

34%

66%

104 / 340 Classifica in Healthcare

AtriCure Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 ago 2026, 20:06 UTC

AtriCure Inc. shares are higher during Monday's session, regaining ground after an earlier pullback. Broader market trends support positive investor sentiment.

31 lug 2026, 20:03 UTC

News

AtriCure shares are lower amid significant insider selling, including a $233,280 sale by Chief Scientific Officer Vinayak Doraiswamy and options exercised by Board Member Sven Wehrwein.

30 lug 2026, 18:56 UTC

AtriCure Inc's shares are lower today, impacted by declines in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

29 lug 2026, 20:03 UTC

News

AtriCure Inc shares reached a 52-week high of $43.18 following better-than-expected quarterly earnings, despite a pullback earlier in the session.

28 lug 2026, 19:21 UTC

AtriCure Inc's shares are higher today amid stronger gains in U.S. and European indices, with no specific company news identified for the movement.

27 lug 2026, 20:02 UTC

News

AtriCure Inc shares are higher as the company prepares for two investor conferences and highlights CEO Michael Carrel's leadership appointment.

24 lug 2026, 21:41 UTC

AtriCure Inc. shares traded roughly flat in after-market hours. The stock has performed well recently, positioned near the upper end of its monthly range.

23 lug 2026, 21:51 UTC

News

AtriCure reported strong Q2 results and raised EPS guidance but shares fell in after-market trading, marking the sixth consecutive session of declines.

22 lug 2026, 19:56 UTC

AtriCure Inc shares are trading lower, reaching a session low just before 15:30 ET, despite remaining above the 20-day moving average.

21 lug 2026, 19:16 UTC

AtriCure Inc shares are trading lower today, continuing a trend of declines over the past three sessions, despite gains in the Nasdaq 100 Index.

20 lug 2026, 19:51 UTC

AtriCure Inc continues higher today, maintaining strength since Friday's close, despite a recent pullback earlier in the session.

Confronto tra pari

Modifica del prezzo

AtriCure Inc Previsione

Obiettivo di Prezzo

By TipRanks

22.13% in crescita

Previsioni per 12 mesi

Media 47.29 USD 22.13%

Alto 55 USD

Basso 36 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AtriCure Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a AtriCure Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

104 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo AtriCure Inc

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.